Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
LEXX | US
0.07
7.69%
Healthcare
Biotechnology
31/05/2024
13/04/2026
0.98
0.95
0.99
0.89
Lexaria Bioscience Corp. operates as a biotechnology company. The company develops and out-licenses its DehydraTECH combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins pain medications hormones PDE5 inhibitors antivirals oral nicotine and its analogs and various cannabinoids. The company's DehydraTECH technology evaluates for a variety of therapeutic indications including hypertension heart disease dementia and diabetes. It is suitable for a variety of product formats such as pharmaceuticals nutraceuticals over the counter and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is based in Kelowna Canada.
View LessLow Debt to Equity (< 0.25)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
129.8%1 month
106.4%3 months
89.1%6 months
104.4%-
-
4.42
0.01
0.01
-7.22
88.51
-
-4.53M
15.49M
15.49M
-
-2.07K
-
8.10
-70.66
1.80
2.05
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.32
Range1M
0.41
Range3M
0.48
Rel. volume
0.65
Price X volume
124.75K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Cingulate Inc. Common Stock | CING | Biotechnology | 5.5 | 16.74M | -4.51% | n/a | 10.72% |
| Aytu BioScience Inc | AYTU | Biotechnology | 2.63 | 16.17M | 3.14% | n/a | 54.59% |
| Longeveron Inc. Class A Common Stock | LGVN | Biotechnology | 1.12 | 16.08M | -3.45% | n/a | 11.72% |
| VistaGen Therapeutics Inc | VTGN | Biotechnology | 0.576 | 15.58M | 2.78% | n/a | 1.90% |
| Marker Therapeutics Inc | MRKR | Biotechnology | 1.74 | 15.53M | -0.57% | n/a | 0.00% |
| HCW Biologics Inc. Common Stock | HCWB | Biotechnology | 0.3522 | 15.37M | -3.37% | n/a | -159.13% |
| DarT Bioscience Inc | DARE | Biotechnology | 1.78 | 15.21M | -2.73% | 0.12 | 218.34% |
| Cocrystal Pharma Inc | COCP | Biotechnology | 1.43 | 14.55M | 14.40% | n/a | 10.24% |
| NeuroSense Therapeutics Ltd. Ordinary Shares | NRSN | Biotechnology | 0.7108 | 14.08M | 1.54% | n/a | -2.11% |
| JSPR | JSPR | Biotechnology | 0.919 | 13.88M | 14.55% | n/a | 2.31% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 10.4 | 15.84M | -11.56% | n/a | 204.46% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.8799 | 12.86M | -18.53% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6 | 11.59M | -0.17% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.33 | 3.40M | -0.75% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.2276 | 2.17M | -10.25% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.07 | 1.14M | -0.96% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -7.22 | 0.53 | Cheaper |
| Ent. to Revenue | 88.51 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.42 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 89.06 | 72.80 | Riskier |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 15.49M | 3.66B | Emerging |